fashion -WSS

fashion

author：Wikipedia 2025-09-06 01:55:41 - browse：37

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： What the Wegovy shortage looks like for doctors — and for patients

focus

WSS

House GOP plan to stem drug shortages differs from Democrats’

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Doctors increasingly discourage vaping amid mounting health concerns

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

What AstraZeneca

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Researchers CRISPR chickens in bid to protect them from bird flu

Activists slam private health insurers over coverage restrictions

There’s no way to know how good AI health technologies are

Sports medicine is finally prioritizing gender equality

STAT Readout: Today's biotech news includes Sana and Amylyx

Supreme Court strikes down use of affirmative action

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD podcast: Merger Mondays, Ozempic panic

focus

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

There’s no way to know how good AI health technologies are

Doctors in states that ban abortion can still help patients

Doctors increasingly discourage vaping amid mounting health concerns

Peter Marks talks Operation Warp Speed for Rare Diseases

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

entertainment

focus

leisure time

hotspot